The short version of reverse-phase HPLC fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
Long-term storage is generally at minus twenty degrees Celsius or colder, preferably desiccated and protected from light. Lyophilized material is more stable than reconstituted solution, which degrades faster at room temperature. Stability depends on pH, ionic strength, and the presence of oxidising agents. Published stability data for the peptide are limited, so storage claims in catalogues should be treated as general guidance rather than measured guarantees. Freeze-thaw cycles are kept to a minimum.
Identity and purity are normally confirmed by reversed-phase high-performance liquid chromatography and mass spectrometry. The expected mass for the acetylated 28-residue peptide is close to 3108 daltons, and a mass shift indicates a modification or truncation. Peptide mapping after enzymatic digestion can resolve sequence-level questions. Counter-ion content, water content, and residual solvents are separate quality attributes that a certificate of analysis may or may not report. Aggregation is monitored by size-exclusion chromatography when relevant.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C129H215N33O55 | Calculated for the acetylated 28-residue peptide |
| Appearance | White to off-white powder | Lyophilized solid recovered from aqueous buffer |
| Solubility | Freely soluble in water | Typically dissolved in water or buffer before use |
| Typical storage | -20 C or below, desiccated | Protect from light and avoid repeated freeze-thaw cycles |
| Identity testing | Reverse-phase HPLC with mass spectrometry | Retention time and measured mass confirm the sequence |
Lyophilized material is generally held at reduced temperature to slow degradation, and storage at minus twenty degrees Celsius or lower is common practice for long-term retention. Short-term working portions are often kept between two and eight degrees Celsius. Once dissolved, the peptide is less stable than the dry powder, and repeated freeze-thaw cycles are associated with loss of material and with aggregate formation. Vials are usually allowed to reach room temperature before opening so that condensation does not introduce moisture, and solutions are protected from light where practical.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography, which separates the peptide from closely related impurities and from truncated or oxidized variants. Mass spectrometry supplies the molecular mass and confirms the expected sequence length, while amino acid analysis can be used to check composition. Because the molecule has no chromophore beyond the peptide backbone, ultraviolet detection is typically performed at a low wavelength, where baseline interference from solvents and buffers is a practical concern. Water content and counter-ion content are often reported alongside purity.
Lyophilized thymosin alpha 1 is typically stored refrigerated at 2 to 8 degrees Celsius and kept away from light. Reconstituted solutions are less stable and are usually used promptly after preparation. Repeated freeze-thaw cycles are avoided because they can promote aggregation and loss of activity. The peptide adsorbs to some plastic and glass surfaces, so a carrier protein is often added to dilute working solutions. Manufacturer instructions and published protocols both govern handling.
Identity and purity testing for thymosin alpha 1 relies mainly on reversed-phase high-performance liquid chromatography and mass spectrometry. Chromatography separates the parent peptide from truncated or modified variants, while mass spectrometry confirms the expected molecular mass. Amino acid analysis and peptide mapping provide additional sequence confirmation. Counterion content, water content, and residual solvents are measured separately as part of specification testing. No single method captures every attribute, so laboratories combine several techniques.
The peptide lacks cysteine, methionine, and tryptophan, so disulfide scrambling and sulfur oxidation are not major degradation routes. Instead, aspartate residues can undergo isomerization or cyclization to succinimide intermediates, generating isoaspartate variants. Hydrolysis of peptide bonds also occurs slowly in solution. These changes may reduce biological activity even when the main peak remains detectable. Stability studies therefore track both potency and the appearance of related substances.
The lyophilized peptide is a white to off-white powder that dissolves freely in water and in aqueous buffers near neutral pH. Because the molecule carries a net negative charge under physiological conditions, saline and phosphate solutions are the usual vehicles, while strongly acidic media are avoided. Stock solutions are commonly divided into small aliquots so that repeated freezing and thawing can be limited, since cycling may encourage aggregation. Solubility in organic solvents is poor and those solvents are seldom used as primary diluents.
Recommended storage for the dry powder is a freezer near minus twenty degrees Celsius, kept desiccated and away from light. Once dissolved, the peptide is less stable and is usually held at two to eight degrees Celsius for short intervals or frozen for longer storage. Stability studies focus on the acetylated terminus and the disulfide linkage because those features define the intact molecule. Common degradation routes include cysteine oxidation, deamidation of asparagine or glutamine side chains, and slow formation of higher-molecular-weight species.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
The activity of this peptide is generally described as immunomodulatory rather than directly antimicrobial. Experimental work links it to signaling through certain Toll-like receptors on dendritic cells and to downstream maturation of antigen-presenting cells. Reported effects include expansion of T cell subsets, shifts in cytokine profiles, and increased natural killer cell activity. These observations come largely from cell culture and animal models, and the precise receptor-level events in humans remain incompletely characterized.
== Ownership and finance == Marks and Hazan initially supported GYG with their own money. In 2009, they sold a minority stake to Peter Ritchie, Guy Russo and Steve Jermyn, who had previously been involved with McDonald's Australia. Russo was subsequently appointed chairman of the board. The board also includes co-founder Robert Hazan, Tom Cowan of TDM Growth Partners, Rokt CEO Bruce Buchanan, and three former McDonalds executives. Investment firm TDM Growth Partners bought a stake in the company for $44 million in August 2018. In December 2020, the publicly listed Magellan Financial Group bought 10% of the company for $86.8 million. In May 2022, Magellan sold its 11.6% stake in the company to an entity owned by investment bank Barrenjoey Capital Partners for $140 million. Marks stated in 2019 that his goal was to list GYG on the Australian Securities Exchange. In 2020, he stated that he was also ambitious to expand the company's presence in the United States, citing Australia's "antiquated" labour laws, high rents, and expensive fresh produce. Marks resigned as CEO due to a health scare in May 2023, but he changed his mind and remained. Hilton Brett was appointed co-CEO in October 2023. GYG was listed on the Australian Securities Exchange on 20 June 2024.
== History == 2C-B was first synthesized and evaluated by American chemist Alexander Shulgin in 1974. He described the properties and effects of 2C-B in humans, along with those of 2C-D, in the scientific literature in 1975. Shulgin proposed 2C-B and 2C-D for use in psychedelic-assisted psychotherapy. However, it was reportedly abandoned for such purposes due to gastrointestinal side effects and lack of entactogenic effects. 2C-B was Shulgin's favorite psychedelic of his own creations, though he has said that he only tried it a few times.
=== Under development === Nivasorexant (ACT-539313) – selective OX1 antagonist – under development for binge eating disorder and previously for anxiety disorders, up to phase 2 – half-life 3–7 hours Seltorexant (MIN-202, JNJ-42847922, JNJ-922) – selective OX2 antagonist – under development for major depressive disorder, insomnia, and sleep apnea, up to phase 3 – half-life 2–3 hours Tebideutorexant (JNJ-61393215, JNJ-3215) – selective OX1 antagonist – under development for major depressive disorder, no development reported for anxiety disorders and panic disorder, up to phase 2 – half-life 14–25 hours
Shorter HRTs support the development of non-exoelectrogenous bacteria which can reduce the Coulombic efficiency electrochemical performance of the fuel cell if the anodophiles must compete for resources or if they do not have ample time to effectively degrade nutrients.
Sources: en.wikipedia.org
== Manufacturing == PRP is prepared by taking blood from the person, and then putting it through centrifugation designed to separate PRP from platelet-poor plasma and red blood cells. This is usually done in the clinic, using commercially available kits and equipment. The resulting substance varies from person to person and from facility to facility.
For human and animal health, both the FDA and the EC have regulated the content levels of toxins in food and animal feed. Fusaric acid Fusarochromanone Kojic acid Lolitrem B Moniliformin 3-Nitropropionic acid Nivalenol Ochratoxins – In Australia, The Limit of Reporting (LOR) level for ochratoxin A (OTA) analyses in 20th Australian Total Diet Survey was 1 μg/kg, whereas the EC restricts the content of OTA to 5 μg/kg in cereal commodities, 3 μg/kg in processed products and 10 μg/kg in dried vine fruits. Oosporeine Patulin – Currently, this toxin has been advisably regulated on fruit products. The EC and the FDA have limited it to under 50 μg/kg for fruit juice and fruit nectar, while limits of 25 μg/kg for solid-contained fruit products and 10 μg/kg for baby foods were specified by the EC. Phomopsins Sporidesmin A Sterigmatocystin Tremorgenic mycotoxins – Five of them have been reported to be associated with molds found in fermented meats. These are fumitremorgen B, paxilline, penitrem A, verrucosidin, and verruculogen. Trichothecenes – sourced from Cephalosporium, Fusarium, Myrothecium, Stachybotrys, and Trichoderma. The toxins are usually found in molded maize, wheat, corn, peanuts and rice, or animal feed of hay and straw. Four trichothecenes, T-2 toxin, HT-2 toxin, diacetoxyscirpenol (DAS), and deoxynivalenol (DON) have been most commonly encountered by humans and animals. The consequences of oral intake of, or dermal exposure to, the toxins will result in alimentary toxic aleukia, neutropenia, aplastic anemia, thrombocytopenia and/or skin irritation.
=== Physical === Physical deterioration of waterlogged wood can happen immediately through the evaporation of the water. If this happens rapidly, the cells in the wood can shrink and collapse. This damage might be inevitable depending on accessibility to treatment. Additionally waterlogged wood should never be handled extensively or put on exhibit for long periods of time. Most waterlogged wood is such that decayed wood cells in the material fill with water. Depending on the wood type and how long the wood has been in water, removal of the water from the cells too rapidly (in the form of natural drying or other) could apply major stress to the cell walls and cause them to collapse. Improperly dried waterlogged irreversibly shrinks, warps, cracks and there is risk of loss to the original surface.
Sources: en.wikipedia.org
Most perceivable colors can be formed by mixing different amounts of three primary colors. This allows precise dynamic color control. Their emission power decays exponentially with rising temperature, resulting in a substantial change in color stability. Such problems hinder industrial use. Multicolor LEDs without phosphors cannot provide good color rendering because each LED is a narrowband source. LEDs without phosphors, while a poorer solution for general lighting, are the best solution for displays, whether they are LCD-backlit or direct LED-based pixels. Dimming a multicolor LED source to match the characteristics of incandescent lamps is difficult because manufacturing variations, age, and temperature change the actual color value output. To emulate the appearance of dimming in incandescent lamps, LEDs may require a feedback system with color sensor to actively monitor and control the color.
== See also == List of University of California, Berkeley faculty List of University of California, Berkeley alumni in business and entrepreneurship List of University of California, Berkeley alumni in science and technology
=== Papillitis/hypertrophy === Papillitis refers to inflammation of the papillae, and sometimes the term hypertrophy is used interchangeably. In foliate papillitis the foliate papillae appear swollen. This may occur due to mechanical irritation, or as a reaction to an upper respiratory tract infection. Other sources state that foliate papilitis refers to inflammation of the lingual tonsil, which is lymphoid tissue.
Sources: en.wikipedia.org
It is a 28-amino-acid peptide originally purified from a bovine thymic extract and later produced synthetically. It is studied mainly for its effects on immune cell function.
No. The two peptides share part of a name but differ in length, sequence, and net charge. Literature searches that treat them as one compound return misleading results.
Solid-phase peptide synthesis is the usual route, and recombinant expression has also been described. Both approaches produce material matching the natural sequence.
Lyophilized powder is normally kept at minus twenty degrees Celsius or below, in a sealed container, desiccated and away from light. Reconstituted solutions are less stable and are usually refrigerated and used quickly. Repeated temperature cycling should be avoided.